🟢 ANIX is trading 12.5% up today following positive ovarian cancer CAR-T trial data

ANIX is trading at $3.33 (12.5% up) in after-hours trading following positive clinical updates from its ovarian cancer CAR-T trial.

• The trial successfully advanced to its highest dose level with no dose-limiting toxicities and reported positive survival data.
• The after-hours rebound suggests a reversal of the sell the news sentiment that pressured the stock during the regular trading session.
• The price action is primarily driven by company-specific trial results rather than broader market indices.